+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Biosimilars Market 2018-2022 - Product Image

Global Biosimilars Market 2018-2022

  • ID: 4720640
  • Report
  • Region: Global
  • 111 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer
  • MORE
About this market

Patients and physician’s willingness to switch to biosimilars is expected to drive growth in the market. Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars. The analysts have predicted that the biosimilars market will register a CAGR of almost 35% by 2022.

Market Overview

Price advantage of biosimilars over biologics

High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.

Market access barriers for biosimilars

To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.

For the detailed list of factors that will drive and challenge the growth of the biosimilars market during the 2018-2022, view the report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer, the competitive environment is quite intense. Factors such as the patients and physician’s willingness to switch to biosimilars and the price advantage of biosimilars over biologics, will provide considerable growth opportunities to biosimilars manufactures. Amgen, Biogen, Merck, Novartis, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
  • Comparison by application
  • Oncology and hematology - Market size and forecast 2017-2022
  • Endocrinology - Market size and forecast 2017-2022
  • Immunology - Market size and forecast 2017-2022
  • Nephrology - Market size and forecast 2017-2022
  • Market opportunity by application
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Americas - Market size and forecast 2017-2022
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Patients and physician’s willingness to switch to biosimilars
  • Therapeutic interchangeability regulations for biosimilars across countries
  • Biosimilar "patent dance"
  • Many originator companies entering the biosimilar market
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Biosimilars approved by US FDA in 2017 and 2018
Exhibit 06: Biosimilars approved by EMA in 2017 and 2018
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global - Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Global - Year-over-year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2017
Exhibit 20: Application - Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Oncology and hematology - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Oncology and hematology - Year-over-year growth 2018-2022 (%)
Exhibit 24: Endocrinology - Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Endocrinology - Year-over-year growth 2018-2022 (%)
Exhibit 26: Immunology - Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Immunology - Year-over-year growth 2018-2022 (%)
Exhibit 28: Nephrology - Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Nephrology - Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by application
Exhibit 31: Customer landscape
Exhibit 32: Global - Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 35: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 38: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 41: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in Americas
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amgen - Overview
Exhibit 49: Amgen - Business segments
Exhibit 50: Amgen - Organizational developments
Exhibit 51: Amgen - Geographic focus
Exhibit 52: Amgen - Key offerings
Exhibit 53: Biogen - Overview
Exhibit 54: Biogen - Business segments
Exhibit 55: Biogen - Organizational developments
Exhibit 56: Biogen - Geographic focus
Exhibit 57: Biogen - Key offerings
Exhibit 58: Merck - Overview
Exhibit 59: Merck - Business segments
Exhibit 60: Merck - Organizational developments
Exhibit 61: Merck - Geographic focus
Exhibit 62: Merck - Segment focus
Exhibit 63: Merck - Key offerings
Exhibit 64: Novartis - Overview
Exhibit 65: Novartis - Business segments
Exhibit 66: Novartis - Organizational developments
Exhibit 67: Novartis - Geographic focus
Exhibit 68: Novartis - Segment focus
Exhibit 69: Novartis - Key offerings
Exhibit 70: Pfizer - Overview
Exhibit 71: Pfizer - Business segments
Exhibit 72: Pfizer - Organizational developments
Exhibit 73: Pfizer - Geographic focus
Exhibit 74: Pfizer - Segment focus
Exhibit 75: Pfizer - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer
  • MORE
Global Biosimilars Market 2018-2022

The author of the report recognizes the following companies as the key players in the global biosimilars market: Amgen, Biogen, Merck, Novartis, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the patients and physician’s willingness to switch to biosimilars.”

According to the report, one of the major drivers for this market is the price advantage of biosimilars over biologics.

Further, the report states that one of the major factors hindering the growth of this market is the market access barriers for biosimilars.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4720640
Adroll
adroll